\BOOKMARK [1][-]{section*.1}{Abstract}{}% 1
\BOOKMARK [1][-]{section*.2}{Resumen}{}% 2
\BOOKMARK [1][-]{section*.4}{Index of figures}{}% 3
\BOOKMARK [1][-]{section*.5}{List of tables}{}% 4
\BOOKMARK [1][-]{section*.6}{Summary}{}% 5
\BOOKMARK [1][-]{section*.7}{Introduction}{}% 6
\BOOKMARK [2][-]{subsection.1.1.1}{Protein are essential molecules}{section*.7}% 7
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{Protein structure}{subsection.1.1.1}% 8
\BOOKMARK [3][-]{subsubsection.1.1.1.2}{Protein Structure Determination}{subsection.1.1.1}% 9
\BOOKMARK [3][-]{subsubsection.1.1.1.3}{Protein Structure Prediction}{subsection.1.1.1}% 10
\BOOKMARK [3][-]{subsubsection.1.1.1.4}{Homology modeling}{subsection.1.1.1}% 11
\BOOKMARK [3][-]{subsubsection.1.1.1.5}{Protein function}{subsection.1.1.1}% 12
\BOOKMARK [3][-]{subsubsection.1.1.1.6}{Protein-Ligand Interactions}{subsection.1.1.1}% 13
\BOOKMARK [3][-]{subsubsection.1.1.1.7}{Protein-ligand binding energetics}{subsection.1.1.1}% 14
\BOOKMARK [3][-]{subsubsection.1.1.1.8}{Protein-ligand prediction}{subsection.1.1.1}% 15
\BOOKMARK [3][-]{subsubsection.1.1.1.9}{Comparative docking approach}{subsection.1.1.1}% 16
\BOOKMARK [2][-]{subsection.1.1.2}{Drug discovery}{section*.7}% 17
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{Computational drug discovery}{subsection.1.1.2}% 18
\BOOKMARK [2][-]{subsection.1.1.3}{Drug discovery in Tuberculosis}{section*.7}% 19
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{Research strategies against MTB.}{subsection.1.1.3}% 20
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{In-silico approaches in TB}{subsection.1.1.3}% 21
\BOOKMARK [2][-]{subsection.1.1.4}{Targeted cancer therapies}{section*.7}% 22
\BOOKMARK [3][-]{subsubsection.1.1.4.1}{Monoclonal antibodies}{subsection.1.1.4}% 23
\BOOKMARK [3][-]{subsubsection.1.1.4.2}{Small molecule kinase inhibitors}{subsection.1.1.4}% 24
\BOOKMARK [3][-]{subsubsection.1.1.4.3}{Resistance to targeted cancer therapies}{subsection.1.1.4}% 25
\BOOKMARK [2][-]{subsection.1.1.5}{Motivation}{section*.7}% 26
\BOOKMARK [1][-]{section.1.2}{Objectives}{}% 27
\BOOKMARK [1][-]{section.1.3}{Results}{}% 28
\BOOKMARK [2][-]{subsection.1.3.1}{Ligand-Target Prediction by Structural Network Biology using nAnnolyze}{section.1.3}% 29
\BOOKMARK [2][-]{subsection.1.3.2}{Target Prediction for an Open Acess Set of Compounds Active against Mycobacterium tuberculosis}{section.1.3}% 30
\BOOKMARK [2][-]{subsection.1.3.3}{Rational design of non-resistant targeted cancer therapies}{section.1.3}% 31
\BOOKMARK [1][-]{section.1.4}{Discussion}{}% 32
\BOOKMARK [2][-]{subsection.1.4.1}{nAnnolyze: predicting large scale, structurally detailed ligand-target interaction using a network-based representation}{section.1.4}% 33
\BOOKMARK [3][-]{subsubsection.1.4.1.1}{Main findings}{subsection.1.4.1}% 34
\BOOKMARK [3][-]{subsubsection.1.4.1.2}{Impact of the presented research}{subsection.1.4.1}% 35
\BOOKMARK [3][-]{subsubsection.1.4.1.3}{Limitations}{subsection.1.4.1}% 36
\BOOKMARK [3][-]{subsubsection.1.4.1.4}{Future perspectives}{subsection.1.4.1}% 37
\BOOKMARK [2][-]{subsection.1.4.2}{Summary}{section.1.4}% 38
